Swedish Orphan Biovitrum AB: Aspaveli (pegcetacoplan) receives positive CHMP opinion for treatment of PNH

STOCKHOLM, Oct. 15, 2021 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) (STO:SOBI) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announce today that the Committee for Medicinal

Related Keywords

Sweden ,United States ,Stockholm ,America ,Swedish ,Aspaveli Empaveli ,Federico Grossi ,Maria Kruse ,Ravi Rao ,Meredith Kaya ,Thomas Kudsk Larsen ,Lissa Pavluk ,European Commission ,Sobi Investor Relations Team ,Nasdaq ,Apellis Pharmaceuticals Inc ,European Medicines Agency ,Committee For Medicinal Products Human Use ,Head Of Research Development ,Apellis Pharmaceuticals ,Medicinal Products ,Human Use ,Chief Medical Officer ,New England Journal ,North America ,Middle East ,Swedish Orphan Biovitrum ,Kudsk Larsen Head ,Kruse Director ,Sobi Media ,Hemolysis Due ,Paroxysmal Nocturnal ,Orphan ,Iovitrum ,Spaveli ,Pegcetacoplan ,Eceives ,Positive ,Thmp ,Opinion ,Treatment ,